Stock INFI.Q INFINITY PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Infinity Pharmaceuticals, Inc. 0.00% -99.96%
Mar. 25 North American Morning Briefing : Tech in Focus on -2- DJ
Mar. 25 Infinity Pharmaceuticals, Inc. Went Out of Business CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 102.9 67.1 54.75 136.1 200.3 49.59
Enterprise Value (EV) 1 51.34 8.512 44.24 154.4 170.6 60.62
P/E ratio -2.45 x -5.81 x -1.16 x -3.13 x -4.25 x -1.11 x
Yield - - - - - -
Capitalization / Revenue 17.2 x 3.03 x 18 x 79.2 x 108 x 19.1 x
EV / Revenue 8.56 x 0.38 x 14.5 x 89.8 x 91.8 x 23.4 x
EV / EBITDA -1.48 x -0.73 x -0.97 x -4.06 x -3.83 x -1.37 x
EV / FCF -2.12 x -3.87 x -1.5 x -6.69 x -7.56 x -2.47 x
FCF Yield -47.2% -25.9% -66.5% -14.9% -13.2% -40.6%
Price to Book 2.16 x 1.28 x 7.09 x -5.93 x 9.3 x -2.6 x
Nbr of stocks (in thousands) 50,711 56,867 57,029 64,207 89,015 89,346
Reference price 2 2.030 1.180 0.9600 2.120 2.250 0.5550
Announcement Date 3/15/18 3/14/19 3/3/20 3/16/21 3/29/22 3/28/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 6 22.15 3.049 1.719 1.858 2.593
EBITDA 1 -34.73 -11.74 -45.44 -38.01 -44.6 -44.39
EBIT 1 -36.44 -11.93 -45.66 -38.5 -45.08 -44.84
Operating Margin -607.42% -53.87% -1,497.67% -2,239.5% -2,426.43% -1,729.43%
Earnings before Tax (EBT) 1 -42.55 -11.25 -47.11 -40.49 -45.26 -44.37
Net income 1 -41.83 -11.25 -47.06 -40.49 -45.26 -44.37
Net margin -697.17% -50.81% -1,543.36% -2,355.56% -2,436.06% -1,711.11%
EPS 2 -0.8273 -0.2031 -0.8258 -0.6765 -0.5300 -0.5000
Free Cash Flow 1 -24.21 -2.202 -29.43 -23.07 -22.58 -24.59
FCF margin -403.57% -9.94% -965.16% -1,342.34% -1,215.36% -948.4%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/15/18 3/14/19 3/3/20 3/16/21 3/29/22 3/28/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 0.467 0.512 0.428 0.451 0.652 0.686 0.712 0.543 0.731
EBITDA -11.46 -11.13 -10.63 -11.38 - - - - -
EBIT 1 -11.58 -11.25 -10.75 -11.5 -12.41 -12.02 -10.88 -9.538 -11.51
Operating Margin -2,480.09% -2,197.46% -2,511.68% -2,549.89% -1,902.91% -1,751.9% -1,528.23% -1,756.54% -1,574.15%
Earnings before Tax (EBT) 1 -11.63 -11.27 -10.71 -11.65 -12.44 -11.99 -10.72 -9.23 -11.04
Net income 1 -11.63 -11.27 -10.71 -11.65 -12.44 -11.99 -10.72 -9.23 -11.04
Net margin -2,490.15% -2,200.98% -2,503.04% -2,583.37% -1,907.36% -1,747.23% -1,505.2% -1,699.82% -1,510.94%
EPS 2 -0.1500 -0.1300 -0.1200 -0.1300 -0.1400 -0.1300 -0.1200 -0.1100 -0.1200
Dividend per Share - - - - - - - - -
Announcement Date 5/13/21 7/27/21 11/2/21 3/29/22 5/3/22 8/9/22 11/14/22 3/28/23 5/9/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - 18.2 - 11
Net Cash position 1 51.6 58.6 10.5 - 29.7 -
Leverage (Debt/EBITDA) - - - -0.48 x - -0.2486 x
Free Cash Flow 1 -24.2 -2.2 -29.4 -23.1 -22.6 -24.6
ROE (net income / shareholders' equity) -64.3% -22.5% -156% 531% 6,384% -3,521%
ROA (Net income/ Total Assets) -24.6% -12.5% -52.3% -54.5% -45.4% -44.2%
Assets 1 169.9 90.23 90.05 74.33 99.68 100.5
Book Value Per Share 2 0.9400 0.9200 0.1400 -0.3600 0.2400 -0.2100
Cash Flow per Share 2 0.6800 0.8500 0.3900 0.4400 0.9100 0.4300
Capex 1 0.04 - 2.33 0.04 0.01 0.02
Capex / Sales 0.72% - 76.32% 2.5% 0.59% 0.66%
Announcement Date 3/15/18 3/14/19 3/3/20 3/16/21 3/29/22 3/28/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INFINITY PHARMACEUTICALS, INC. Stock Infinity Pharmaceuticals, Inc.
-99.96% 90
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INFI.Q Stock
  4. Financials Infinity Pharmaceuticals, Inc.